糖尿病視網膜病變（Diabetic retinopathy）是一種因慢性高血糖症合併其他全身性異常疾病所引發之嚴重損害視覺之併發症。目前標準預防及治療規範包括嚴格血糖及血壓控制以及視網膜雷射光凝固法來治療新生血管及臨床顯著黃斑部水腫。這篇文章將探討目前正在研究之血管內皮生長因子抑制劑vascular endothelial growth factor (VEGF) inhibitors, 蛋白質激   抑制劑protein kinase C (PKC) inhibitors,色素內皮層衍生因子誘發物pigment endothelium-derived factor (PEDF) inducers, octreotide, 血管壓力接受體阻斷劑angiotensin II receptor blockers (ARBs), 以及triamcinolone acetonide等藥物對糖尿病視網膜病變之治療成效。

Diabetic retinopathy (DR) is a potentially visually devastating complication of chronic hyperglycemia and other associated systemic abnormalities. Currently, the standard method for prevention and treatment includes intensive glycemic, blood pressure control, laser photocoagulation for neovascularization and clinically significant macular edema. This article involving vascular endothelial growth factor (VEGF) inhibitors, protein kinase C (PKC) inhibitors, pigment endothelium-derived factor (PEDF) inducers, octreotide, angiotensin II receptor blockers (ARBs) and triamcinolone acetonide (TAAC) will be discussed.